Abstract
Angiosarcomas are rare soft-tissue tumors of endothelial cell origin. They are associated with high rates of local recurrence and poor prognosis1. The standard of care for cutaneous angiosarcomas is surgical excision. In some cases, surgery is not possible because too mutilating. In these indications, only few chemotherapeutic drugs are available, i.e.paclitaxel or doxorubicin (with a progression-free survival (PFS) of 3.7-5.4 months for doxorubicin2).
This article is protected by copyright. All rights reserved.
http://ift.tt/2ialzAt
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου